purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation elan earnings call period ending december image source motley fool elanco animal health elan q earnings callfeb etcontents prepared remark question answer call participant prepared remark operatorgood morning name krista conference operator today time would like welcome everyone elanco animal health fourth quarter earnings conference call line placed mute prevent background noise speaker remark questionandanswer session operator instruction would like turn conference katy grissom head investor relation katy may beginkaty grissom head investor relation good morning thank joining u elanco animal health fourth quarter full year earnings call katy grissom head investor relation joining today call jeff simmons president chief executive officer todd young chief financial officer scott purucker investor relation slide referenced call available investor relation section elancocom today discussion include forwardlooking statement statement based current assumption expectation subject risk uncertainty could cause actual result differ materially forecast information see risk factor today earnings press release well latest form k q filed secwe undertake duty update forwardlooking statement remark today focus nongaap financial measure reconciliation nongaap measure included appendix today slide earnings press release prepared remark happy take question turn call jeff jeff simmons president chief executive officer thanks katy good morning everyone today elanco reported fourth quarter full year result strong performance last year give u confidence innovation portfolio productivity strategy working action investment launch new innovation optimize core portfolio paying enter focused advancing strategy deliver three priority sustained revenue growth innovation improved cash conversion starting slide revenue growth fourth quarter delivered constant currency revenue growth line performance third quarter fourth quarter growth driven innovation strength across farm animal business improved condition european pet health retail market increased price exceeded sale expectation demonstrated strong operating expense management quarter adjusted ebitda adversely impacted approximately million unexpected item primarily related devaluation argentinian peso occurred december fourth quarter sale growth driver along strength yous pet health retail business led return full year constant currency sale growth importantly expect growth continue even potential upside latestage pipeline innovation made significant progress approval launch canine parvovirus monoclonal antibody cpma adtab new overthecounter oral parasiticide europe well submission three latestage potential blockbuster product path toward approval first half exceeded expectation innovation revenue outlook put u track deliver expected million million contribution continue prioritize free cash flow improvement paying debt reducing leverage exceeded debt paydown expectation november guidance expect cash available debt paydown approximately million four time earlier month announced sale aqua business merck animal health allowing u prioritize investment going forward larger market greater earnings potential meaningfully improve leverage profile expect net debt adjusted ebitda midfour time range end year high three time low four time range end importantly making disciplined decision taking action reallocate capital within operation invest future today announced strategic restructuring allow u three thing first shift resource farm animal pet health across international business drive adoption innovation product prepare globalize latestage pipeline also allows u capitalize efficiency resulting completion erp system integration concentrate role strategic location lastly allows u transition business model distribution thirdparty model certain market notably argentina restructuring impact approximately personnel global workforce expected deliver net saving million million annualizing million million saving beyond saving reinvested area significant valuecreation opportunity specifically pet health globally livestock sustainability expect limited amount topline headwind shift distribution market expect restructuring effort meaningful downside sale otherwise notably international farm animal market expect realize saving strong track record delivering productivity continue look additional opportunity efficiently allocate capital credit senior leadership proactive action believe set elanco deliver next era growth moving slide full year constant currency revenue growth led farm animal saw marked improvement pet health business well starting farm animal four percent constant currency revenue growth full year farm animal represented accelerated growth rate poultry cattle swine compared team executed across business especially place strong market position notably international poultry yous cattle international farm animal largest revenue contributor four quadrant delivered constant currency revenue growth primarily driven increased price strengthened poultry result robust underlying demand share growth key market like youk brazil china yous farm animal business also delivered growth driven increased price strength cattle swine poultry improving fourth quarter experior delivered million fourth quarter expected annualized run rate million shared november remain encouraged experiors progress expect continued growth product globally moving pet health global revenue declined constant currency representing encouraging improvement constant currency decline yous pet health business revenue declined significant improvement decline enhancement share voice physical availability innovation contribution increased price offset competitive pressure vet clinic market otc parasiticide business strong year growing net sale retail channel top six retailer grew dispensing sale unit dollar vet clinic encouraged growth credelio new product like cpma zorbium bexacat look toward investing expanded sale force implementing enhanced incentive drive growth ahead anticipated new innovation launch vet clinic year finally international pet health constant currency revenue decline primarily driven demand pressure spain retail market first half year offset encouraging growth credelio family adtab europe spain situation improved second half year expect market recover first half moving slide cover execution highlight across innovation portfolio productivity strategy starting productivity improving cash conversion continues key priority across organization continue drive crossfunctional effort improve net working capital specifically balance sheet inventory management gradually improved second half year inventory source cash fourth quarter full year paid million gross debt finished yearend leverage time slightly better midpoint november guidance finally earlier year achieved significant milestone completing erp system integration free million free cash flow debt paydown moving portfolio price growth year previous average pet health farm animal core portfolio continues stabilize driven stronger commercial capability global omnichannel approach complement new innovation continue invest highest valuecreation opportunity across commercial rd manufacturing innovation productive year submission new product approval major market advancement early stage pipeline endmarket innovation contributed million revenue representing percentage point growth elanco doubling contribution growth led experior nutriquest farm animal side credelio plus credelio cat adtab cpma pet health side life cycle management geo expansion also contributing across cmpa finished line expectation sale million expanded supply capacity increased marketing effort aimed veterinarian pet owner expected make product key contributor growth latestage pipeline three differentiated asset credelio quattro zenrelia bovaer progressing fda shared previously regulatory process rolling iterative stage ongoing productive dialogue fda center veterinary medicine three potential blockbuster continue path toward yous approval first half focused yous market first product pleased share also completed submission zenrelia nine additional market including eu youk australia additionally team continues deliver targeted life cycle management extends life value existing brand helping stabilize protect core total innovation sale expected million million potential upside three latestage pipeline asset putting u well track deliver million million innovation sale finally marked significant progress early stage portfolio number promising asset next wave expected drive growth second half decade special credit ellen de brabander global rd regulatory team really set elanco deliver significant highimpact innovation major market year ahead cover outlook slide want briefly discus announcement made earlier month sell aqua business approximately billion decision result strategic process started year ago evaluated expected growth driver business future saw opportunity focus investment larger market greater earnings potential namely pet health livestock sustainability aligned pipeline effort expect transaction close around midyear importantly billion expected proceeds transaction combined improved free cash flow business expect accelerate debt paydown deeply grateful aqua team dedication delivering customer well bigger purpose enriching life animal protein moving outlook slide begin year remain confident resilient underlying demand animal care outlook animal health market reflects underlying tailwind humanization pet global protein demand balanced economic condition impacting consumer cyclical profitability factor livestock macroeconomic political tension around world despite believe elanco uniquely wellsuited growth year innovation expectation investment key capability restructuring action experienced team differentiated omnichannel strategy contribute confidence full year expect constant currency revenue growth includes price growth approximately incremental innovation revenue contribution least headwind yearoveryear core volume expected lessen sequentially stabilize base business improved execution lapping well regulatory macroeconomic challenge last year importantly guidance includes aqua business full year excludes contribution three latestage product currently regulatory review fda plan update expectation line quarterly cadence account transaction close product approval year expect revenue growth pet health farm animal pet health see value driver across part omnichannel strategy improved supply innovation led cpma adtab expected tailwind overall sga increasing reallocate investment part business pet health portfolio part expanded yous field force increased investment effort corporate group shifting resource international business support improved share voice importantly increased investment fronthalf loaded increase promotional investment behind marketleading retail otc parasiticide business northern hemisphere flea tick season retail side expanded physical availability new channel like club dollar within existing channel like mass pet specialty grocery effort yous europe paired enhanced brand activation expected drive increased awareness overall pet health business set improved performance growth even ahead anticipated new product parasiticide dermatology moving farm animal also expect growth business globally innovation price offsetting market challenge generic pressure expect poultry cattle remain growth driver livestock sustainability market continues develop functionality carbon credit marketplace validated look toward bovaer approval catalyst expansion durability diversity global farm animal business wellpositioned revenue market share growth turn toddtodd young chief financial officer thank jeff good morning everyone focus comment fourth quarter full year adjusted measure please refer today earnings press release detailed description yearoveryear change reported result starting slide fourth quarter revenue billion increase price growing slide break revenue performance quarter price rate volume well specie region pet health globally declined constant currency quarter yous business declined competitive pressure veterinary clinic partially offset innovation revenue increased price improved retail inventory situation compared reduced purchasing experienced fourth quarter last year international pet health business grew constant currency primarily driven economic rebound europe compared back half last year innovation revenue partially offset soft market dynamic several asian country globally sale seresto grew quarter driven yous implemented lower list price starting december maximize elasticity brand rebound europe described advantage family sale declined quarter primarily driven international market product benefited improved retail inventory situation yous quarter compared last year shifting farm animal global revenue grew constant currency fourth quarter anticipated november guidance yous farm animal growth driven resupply cattle vaccine strong experior growth favorable timing poultry rotation expect yous farm animal strong quarter growth significantly higher expected key contributor u delivering top end revenue guidance solid international farm animal growth driven continued strength international poultry continuing income statement slide gross margin decreased basis point decline driven approximate basispoint headwind slowing manufacturing output work reduce balance sheet inventory well unfavorable manufacturing performance including higherthanexpected inflation certain key input higher affiliate expense including recently implemented higher import duty rate argentina partially offset improved price operating expense declined year year quarter rd expense largely line year year sga declined driven disciplined cost management across business saving completing system integration partially offset higher employeerelated expense moving slide bridge adjusted ebitda adjusted eps guidance november adjusted ebitda million quarter along gross margin headwind unfavorable mix manufacturing performance adversely impacted approximately million unexpected item primarily related argentina adjusted earnings per share quarter adjusted effective tax rate fourth quarter primarily result unfavorable returntoprovision adjustment partially offset benefit certain refundable state income tax credit slide provide comment full year performance delivered billion sale constant currency growth driven improved price adoption new product strengthened international poultry partially offset competitive pressure yous vet clinic soft european economic environment first half last year generic pressure change regulatory requirement yous farm business slide provided additional revenue breakdown including top affiliate certain product continuing pl gross margin decrease basis point compared last year impact slowing manufacturing output inflation partially offset improved price factor combined increase operating expense fourth quarter impact devaluation duty rate argentina resulted adjusted ebitda million full year adjusted earnings per share compared last year coming higher interest expense tax nongaap tax rate increased primarily driven item described impacting fourth quarter moving guidance let offer word cash debt working capital slide operating cash flow million full year million fourth quarter yearoveryear increase fourth quarter reflects improved net working capital performance specifically inventory receivables partially offset higher cash interest cost ended year net debt billion net leverage ratio time reduced gross debt million full year exceeding november expectation million moment touch expectation debt paydown factor improving cash outlook let u move financial guidance starting slide jeff mentioned today guidance includes full year contribution aqua business excludes contribution three key latestage pipeline asset credelio quattro zenrelia bovaer update guidance throughout year reflect evolution topic year expect revenue billion billion approximately constant currency growth expect innovation contribute million million million million growth year year credelio quattro zenrelia bovaer would increase range regardless timing launched expect product accretive ebitda additionally expect revenue headwind approximately million result strategic choice change distribution model primarily argentina exit lowmargin distribution agreement continued phaseout contract manufacturing agreement gross margin expected decline slightly benefit revenue growth offset impact action taking slow manufacturing output reduce balance sheet inventory improve net working capital headwind experienced second half related certain increased operating cost expected continue first half year improving third quarter shifting tailwind fourth quarter operating expense expected increase driven increased employeerelated expense investment commercial capability support pet health business increase expected partially offset reduced expense primarily second half year restructuring announced morning taking advantage efficiency resulting erp system consolidation reallocating resource business area country ability generate greater earnings potential time adjusted ebitda expect million billion anticipate adjusted eps given cadence dynamic gross margin operating expense adjusted ebitda adjusted eps expected decline first half year increase second half year slide provides yearoveryear bridge adjusted ebitda adjusted eps slide appendix provides number additional assumption help support modeling effort slide share first quarter guidance expect revenue billion billion adjusted ebitda million million adjusted eps reminder result erp system blackout approximately million revenue million adjusted ebitda adjusted eps shifted first quarter second quarter addition manufacturing headwind discussed impacting first quarter also increasing investment pet health yous sale force expansion increase promotional investment behind retail otc product given timing northern hemisphere flea tick season making investment starting q advance saving expect realize restructuring announced morning finally share comment cash balance sheet expectation slide expect meaningful improvement free cash flow conversion million million available debt paydown four time million improvement driven reduced project cost notably moving past erp system implementation plus lower cash interest improved net working capital inventory effort offset slightly higher capex support new launch using assumption innovation aqua transaction pl yearend expect net leverage ratio time anticipated billion billion net proceeds aqua transaction expect reduce net leverage midfour range yearend hand back jeff closing commentsjeff simmons president chief executive officer thanks todd enter th year company longeststanding brand animal health humbled opportunity serve customer around globe farmer veterinarian pet owner animal care enter laserfocused three priority sustained revenue growth innovation improved cash conversion importantly management team taking disciplined decisive action improve earnings potential leverage profile time evidenced sale aqua business billion net proceeds restructuring announced today reallocate resource higher valuecreation area investment expanding yous pet health field force enhance share voice maximize innovation highestmargin business area focused effort manage manufacturing throughput improve net working capital performance investing support launch differentiated product year come difficult right decision executing ipp strategy investment improved capability experienced team delivered return topline growth growth continue encouraged strong pipeline next wave innovation expect fuel longterm sustainable growth elanco turn katy moderate qakaty grissom head investor relation thanks jeff would like take question many caller possible ask limit one question one followup operator please provide instruction qa session take first caller question answer operatorthank operator instruction first question come line jon block stifel please go aheadjon block stifel financial corp analyst thanks guy good morning jeff know good see filing mentioned zenrelia ous thought highlevel thought approval timeline eu youk australia know look one competitor believe know actually worldwide inaudible revenue outside united state actually resides certainly seems like material opportunity color potential approval timeline ousjeff simmons president chief executive officer yeah thanks jon yeah made lot progress would say zenrelia fastest product history elanco globalizing major innovation nine major market made submission similar think yous submission final submission case year varies japan australia europe figure count early mode would start get approvalsjon block stifel financial corp analyst got helpful second question might little bit twoparter thought adufa date zenrelia february jeff discus highlevel thought know still remains get done interaction agency increased conviction zenrelia h approval timeline todd quickly pivot know gm arguably sort lower number people head know couple month ago think cadence gm guy usually benefit parasiticides h time trying slow plant going headwind thought around gm cadence throughout thanks guysjeff simmons president chief executive officer yeah jon update today zenrelia timeline continue really change term productive dialogue fda believe know market adoption know driven value execution dialogue fda going well change change course announcing know approval change let know change alltodd young chief financial officer jon thanks question gross margin know full year expect gross margin know pretty close cadence little different still higher gross margin first half year high would last year plant slowdown know first half year slightly lower last year q becomes pretty much line q get tailwind started slow plant q know headwind fourth quarter katy grissom head investor relation thanks next callerjon block stifel financial corp analyst thank youkaty grissom head investor relation thanks jonoperatoryour next question come line erin wright morgan stanley please go aheaderin wright morgan stanley analyst great thanks another one zenrelia talk little bit latest thought gotomarket strategy zenrelia thought differentiation product know leveraging distribution price leverage also positioning online channel given significant category online channel well thanksjeff simmons president chief executive officer yeah thanks erin thanks focus jon know excited entering derm market new market u got zenrelia followed il shortacting differentiated asset next wave innovation ellen made lot progress team year bringing product development pipeline derm added asset market going know key player decade know think come back consistently look market see know still lot unmedicalized dog know leaving vet without treated strong desire choice vet pet owner fundamental believe matter market want choice globalizing jon referenced well know would emphasize continue feel strongly know differentiation going key well look going launch product maybe couple point first keep coming back two important pillar value execution value get around differentiation product product portfolio going look execution know first thing really focused erin getting share voice know level extremely competitive believe got sale force place selling parvo preparing know need create share voice high enough create awareness vet clinic product know get market vet know clinic aware start turn additional factor like digital dtc going staged approach still looking distribution great news got lot option distribution given erp setup intend price value focus know believe innovation rewarded differentiation rewarded focus valuebased pricing approach relative differentiation think last thing know derm u add kind fourth pillar got para got therapy got vaccine think look know corporates vet clinic segment fourth pillar derm total portfolio going give u advantage key part launch strategy well erin thank youerin wright morgan stanley analyst ok thanks restructuring bigger picture around sale aqua continuing evaluate part business segment could evaluate potential divestituresjeff simmons president chief executive officer yeah maybe comment looking mean know concentrating focus let clear pet health livestock sustainability decision sale aqua business restructuring announced today around creating enough resource win align pipeline bigger market greater earnings potential large blockbuster differentiated asset intention know making strategic decision relative segment really would highlight coming restructuring know really three thing comment know made morning shifting resource know market pet health livestock know sustainability think like europe going move much bb approach pig put lot resource pet second going capitalize erp implementation done concentrate role strategic area lastly importantly going transition business model know nonstrategic market like argentina got country people moving additional market like argentina using distribution model allows u know resource double big area pet health livestock sustainabilityoperatoryour next question come line michael ryskin bank america security please go aheadmike ryskin bank america merrill lynch analyst great thanks taking question guy hear mekaty grissom head investor relation yestodd young chief financial officer yesmike ryskin bank america merrill lynch analyst ok great thanks guy first want clarify question guide todd think really clear revenue zenrelia credelio quattro bovaer included guide want clear much cost opex perspective obviously expansion commercial sale force thing like already put place already number incremental spend product get approved let u say get approved let u say go market put digital dtc spend behind second half year already included opex number would also incremental like revenuestodd young chief financial officer mike also incremental say prepared remark expect accretive ebitda ebitda guidance get better launch big threemike ryskin bank america merrill lynch analyst got ok helpful want get clarification like know model would change product get approved appreciate followup question guide think talked price revenue existing innovation know regular credelio galliprant thing like know total business current constant currency volume another year volume could break expecting end market versus specific headwind know legacy portfolio maybe headwind competition help u sort deconvolute volume expectation little bit thankstodd young chief financial officer sure mike know expect volume volume le competition inside vet clinic called previously see trifexis declined know million total revenue still big product u one know greater competition also see know seresto advantage family last year lot vet clinic retail side business yous grew double digit really strong bobby team got point distribution physical availability share voice work volume legacy know experior ramp great know generally take optaflexx different part portfolio impact volume experior ramp overall know continue feel good sale momentum acceleration versus move forward also impact different country volume exit lowmargin distribution flip know argentina market using thirdparty distributor versus internal people groundoperatoryour next question come line balaji prasad barclays please go aheadbalaji prasad barclays analyst hi good morning thanks question firstly regard decline pet health q outlook spoke competitive pressure veterinary clinic help u understand transient otherwise driven new launch competitor factor work also speak enhancing sale force could quantify sale force add think adequately staffed support new launch thank youjeff simmons president chief executive officer yeah thank much yeah know highest level yous pet know would step back say made lot progress yous pet overall highest level think much competitive today seen significant improvement overall engagement team think strategy working todd highlighted term share voice physical availability know innovation price much know competitive organization today know strong year step back look know saw point improvement sequentially minus minus overall see standpoint stronger portfolio share voice stronger team changed incentive sale force overall portfolio stronger start adding bexacat know zorbium parvo parvo opening lot door vet clinic step back question set see nice growth coming ahead know total global pet health business farm animal business contributing growth question competitiveness vet clinic yous high mean without question would say factor would note know always seasonality weather factor economics seen retail side trade know competitive pressure inside vet clinic think wellpositioned bringing innovation know anticipation blockbuster coming omnichannel approach able retail business complementing vet clinic business know probably better indexed relative vet visit companiesoperatoryour next question come line umer raffat evercore isi please go aheadumer raffat evercore isi analyst hi guy thanks taking question two may first language distribution model change could confirm change distributor strategy yous payment term extension yous secondly heading sort quattro launch feedback zoetis starting preempt potentially making free tapeworm treatment available case dog contract tapeworm thinking relative differentiation expectation launchtodd young chief financial officer well let take first one umer pas jeff tapeworm respect distribution really speaking case like argentina jeff mentioned country total people ground country use distributor take product market sell speaking respect yous bringing bear product yous distribution channel reflected guidance material system consolidation able know efficient one way versus two different model running last year jeff jeff simmons president chief executive officer yeah thanks umer yeah excited credelio quattro update timeline continues continue productive dialogue fda know think would back make couple comment think know parasiticides really uninvolved category pet parent vet know vet recommendation key come back core strategy know making sure share voice high noted yes added rep got experience field right know trained adding value speak selling parvo product got share voice second yes differentiation know believe know fundamental key look differentiation know one broader coverage always better full solution know definitely preferred veterinarian second diagnostics match disease evidence today increased diagnostics idexx others around tapeworm concern zoonotic concern well think know second people focus diagnostic side animal health side awareness higher usually lead prevalence think last trend zoonotic concern umer continue especially covid know specific tapeworm look one common tapeworm transmitted flea many tapeworm know relevant domestic dog potential carry tapeworm know serious disease impact always say know else equal would use product coverage approach got right team place preparing launch long history parasiticides broadest portfolio outside vet excited bringing quattro markettodd young chief financial officer one thing umer payment term payment term generally stay always different thing different customer know overall account receivables big inflow cash q strong operating cash flow performance relative previous quarter lot work done team around globe collect cash really focus know one system get arr better wayoperatoryour next question come line glen santangelo jefferies please go aheadglen santangelo jefferies analyst hi yeah thanks taking question two quick one know wanted follow competitive pressure vet clinic sound like certainly making progress kind curious confidence ability take price increase year forecasting know guidance taken already pushback far concernedjeff simmons president chief executive officer yeah first glen thank coverage joining interest research elanco yeah absolutely competitive pressure would believe said much stronger position stronger team stronger portfolio think lot tactic relative think know anticipation innovation well glen really creates know partnership distributor corporate clinic others opened lot door know strong would say even introduction example proofpoint point introduction latest broad spectrum parasiticide actually seeing really know shake share taken within actually le share compared competitive launch taken u think show differentiation segmentation digital thing working set well relative price know continued know execute price valuebased way know innovation always allows u bring price seen know pushback price continue see strong resilience know market lot interest adoption vet side product portfolioglen santangelo jefferies analyst perfect maybe ask one revenue followup trying know triangulate comment innovation sale appreciate want talk point sort guiding people million million sale new innovation product sort know back know done far expecting fair say sort triangulate sort talking respect three pending launchesjeff simmons president chief executive officer yes consistent commitment million million exact math see todd referenced know going experior climb going know overlap product come optaflexx yes start guide know million million year new product launch new product il coming product contribute yes staying feel confident commitment million million end correctoperatoryour next question come chris schott jp morgan please go aheadchris schott jpmorgan chase company analyst great thanks much two question maybe first parvo opportunity additional color much inventory year big product could become maybe think longer term update u exyous opportunity parvo second question gross margin color provide much inventory manufacturing slowdown action gross margin really trying get color underlying trend start think kind beyond year gross margin go thanks muchjeff simmons president chief executive officer yeah thanks chris question parvo take one first land line expectation quarter bigger news yes demonstrated ability scale liter give u confidence got capacity supply really go marketplace full force new sale force right product performing well important think another important note chris product already clinic general practitioner demonstrates know prevalence many clinic seeing seventythree percent adoption clinic general practitioner know shelter market see uptake initially seeing reorder well see product key contributor growth real step year yes would launched also highlight launched pretty significant defender campaign really drive know awareness parvo know right gate got billion impression social medium marketing campaign set charge vet clinic industry pledge save million puppy end decade think creating awareness strong marketing share voice yes next thing starting target key market internationally actually bring product higher prevalence parvo may always typical european market know emerging market well higher parvo see blockbuster potential globalize product good start definitely updating quarter quarter key metric adoptiontodd young chief financial officer chris respect manufacturing slowdown embedded guidance basispoint basispoint headwind plant slowdownsoperatoryour next question come steve scala td cowen please go aheadunknown speaker hi chris steve thanks taking question two first new launch gating factor yous launch postfda approval like statelevel approval building inventory contracting distributor second yous sale force sort initial feedback received positive impact positioning company current portfolio thank jeff simmons president chief executive officer yeah thanks chris real quick noted gating factor expect upon approval typically couple month actually know launch driven heavily manufacturing packaging labeling typical gating factor know lot positive feedback tremendous interest many many application believe selected experienced strong sale force actually transition gone faster believe distraction factor may high expected looking forward sale force added investment first half help u ramp existing sale first halfoperatoryour next question come line navann ty bnp paribas please go aheadnavann ty exane bnp paribas analyst hi good morning thanks taking question first one touched base pricing zenrelia able expand general pricing strategy versus potential differentiation quattro bovaer zenrelia second question clarification eps guidance reflects lower interest expense resulting aqua sale thank youtodd young chief financial officer let take first one navann welcome back coverage reduced interest expense guidance aqua sale interest expense aqua sale happen update guidance aqua postconclusion sale quarterly calljeff simmons president chief executive officer yeah navann product actually see future blockbuster differentiation portfolio know intend price value see past innovation launched believe innovation rewarded part offeringnavann ty exane bnp paribas analyst operatoryour next question katy grissom head investor relation yeah take next caller pleaseoperatoryour next question come nathan rich goldman sachs please go aheadnate rich goldman sachs analyst great thanks question quick one end todd highlighted million million investment pet health first quarter could give u rough split related field force expansion versus might promotional dollar focused parasiticides think maybe underlying kind expense base go otc growth anything specific could share expectation advantage seresto year lastly jeff maybe going back comment kind full innovative portfolio pet health derm parvo could maybe talk mean market flexibility give better access corporate account ability use volume discount additional color would greattodd young chief financial officer sure nate thanks question yes total investment sale force million full year basis know essentially pretty given people pretty standard course year q investment pet health really promotional spend lot drive adtab excited first oral parasiticide otc market europe know part know kind oddity first half second half restructuring announced today going provide lot saving using fund incremental investment behind big opportunity saving secondhalf loaded northern hemisphere parasiticide season really got make investment first half drive uptake product respect seresto family know guiding product today know overall know feeling good positioning retail big place leadership expect leadership continuejeff simmons president chief executive officer yeah relative overall portfolio would say matter segment know enter clinic four dimension mentioned derm new one u really put u unique position know next company able give optionality vet looking segment think major factor major differentiator major animal health company able breadth portfolio derm additionkaty grissom head investor relation thanks take last calleroperatoryour last question today come brandon vazquez william blair please go aheadbrandon vazquez william blair company analyst hey everyone thanks taking question sneaking ask one ask two upfront first fda conversation guy guess get closer approval first half reiterating think maybe would expected could give little bit confidence little narrowing time frame one overreading anything going conversation guy feel confident going discussion maybe second one highlight key couple key product within innovation bucket driving growth thank youjeff simmons president chief executive officer yeah let take second one first know question excited experior experior exceeded million run rate ended year million growth trajectory see shortage cattle number experior play relative value proposition course parvo driver one know talk much restructuring really adding significant investment adtab europe good strong finish year would three key would point look brandon would read anything know confidence remains confidence differentiation remains great asset regulatory team great job proactive productive dialogue cvm update anything changeoperatorthank lady gentleman turn conference jeff simmons closing remarksjeff simmons president chief executive officer know time want say everybody thank time think second half really mark progress momentum two quarter constant currency growth doubled innovation know increased debt paydown beyond expectation look priority remain sustained growth top line innovation bringing innovation forward cash metric inside guide know strong expectation continue make great progress thank interest investment elanco look forward exciting year year high engagement youoperatoroperator signoff duration minutescall participantskaty grissom head investor relationsjeff simmons president chief executive officertodd young chief financial officerjon block stifel financial corp analysterin wright morgan stanley analystmike ryskin bank america merrill lynch analystbalaji prasad barclays analystumer raffat evercore isi analystglen santangelo jefferies analystchris schott jpmorgan chase company analystunknown speakernavann ty exane bnp paribas analystnate rich goldman sachs analystbrandon vazquez william blair company analyst elan analysis earnings call transcript article transcript conference call produced motley fool strive foolish best may error omission inaccuracy transcript article motley fool assume responsibility use content strongly encourage research including listening call reading company sec filing please see term condition additional detail including obligatory capitalized disclaimer liabilitythe motley fool position stock mentioned motley fool disclosure policy